1-4 of 4
Scott B. Hoyt
Close
Sort by
Journal Articles

Kme-0584, a Highly Potent IRAK1/IRAK4/panFLT3 Inhibitor, Is a Promising Clinical Candidate for Hypomethylating Agent Plus Venetoclax Resistant AML/MDS Patients

Jan S. Rosenbaum, Amal S. Kolt, Scott B. Hoyt, Gregory M. Hayes, Brandi L. Soldo, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2023) 142 (Supplement 1): 4152.
https://doi.org/10.1182/blood-2023-189899
Published: 2023
Journal Articles

Paralog-specific signaling by IRAK1/4 maintains MyD88-independent functions in MDS/AML

Joshua Bennett, Chiharu Ishikawa, Puneet Agarwal, Jennifer Yeung, Avery Sampson, Emma Uible, Eric Vick, Lyndsey C. Bolanos, Kathleen Hueneman, Mark Wunderlich, Amal Kolt, Kwangmin Choi, Andrew Volk, Kenneth D. Greis, Jan Rosenbaum, Scott B. Hoyt, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2023) 142 (11): 989–1007.
https://doi.org/10.1182/blood.2022018718
Published: 2023
Includes: Supplemental data
Journal Articles

IRAK1 Contributes to IRAK4 Inhibitor Resistance Via Non-Canonical Signaling Mechanisms in MDS/AML

Josh Bennett, Jennifer Yeung, Avery Sampson, Kathleen Hueneman, Mark Wunderlich, Kwangmin Choi, Andrew Volk, Scott B. Hoyt, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 2240–2241.
https://doi.org/10.1182/blood-2022-167526
Published: 2022
Journal Articles

Inhibition of Both IRAK1 and IRAK4 Is Required for Complete Suppression of NF-Kb Signaling across Multiple Receptor-Mediated Pathways in MDS and AML

Jan S Rosenbaum, Scott B. Hoyt, Amal S. Kolt, Daniel A Luedtke, Craig J. Thomas, Daniel T. Starczynowski
Journal: Blood
Blood (2022) 140 (Supplement 1): 5949–5950.
https://doi.org/10.1182/blood-2022-167783
Published: 2022